The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10 ...

Cencora has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance’s sale ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora Inc’s (NYSE:COR), formerly AmerisourceBergen Corporation, first quarter 2024 adjusted EPS reached $3.28, up from $2.71 Y/Y, beating the consensus of $2.89. In the first quarter ...

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Cencora, a global healthcare company, has expanded its Sure Supply Program to include 200 critical medications, including several oncology treatments, in response to ongoing drug shortages.

Cencora is now targeting an 8% to 10% rise in revenue for the full fiscal year, a lift from its previous guidance for 7% to 9% growth. Sales are expected to rise 9% to 11% in its U.S. healthcare ...

$60,000 of CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.